UPDATE: Sarepta Therapeutics (SRPT) Posts Wider-than-Expected Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months
July 20, 2016 9:48 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results. The analyst continues to expected FDA approval in the next few months.
Gilson commented, "Sarepta on July 19 reported 2Q16 financial results, ending the... More
Stocks with Implied Volatility Movement
July 18, 2016 5:11 AM EDTSarepta Therapeutics (SRPT), Rite Aid (RAD) implied volatility is above its IV index mean
... MoreSanthera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - Oppenheimer
July 15, 2016 10:58 AM EDTOppenheimer analyst, Michele Gilson reiterated her Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) after Santhera announced today that the FDA did not support its plans to file an NDA for Raxone (idebenone) for the treatment of DMD. We do not view this as a... More
